Recent news and publications

News

Researchers make progress understanding a rare pediatric cancer

Vaccine innovation targets high-risk childhood cancers

Publications

 

Articles

Wang B, Li D, Cherkasova V, et al. Cannabinol Inhibits Cellular Proliferation, Invasion, and Angiogenesis of Neuroblastoma via Novel miR-34a/tRiMetF31/PFKFB3 Axis. Cancers (Basel). 2022;14(8):1908. doi:10.3390/cancers14081908

Reynolds CR, Tran S, Jain M, Narendran A. Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies. Vaccines (Basel). 2022;10(2):196. doi:10.3390/vaccines10020196

Grundy M, Narendran A. The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents. Front Pediatr. 2022;10:910268. doi:10.3389/fped.2022.910268

Jain M,  Thakur S, Tran S, Zhang C, Sharma R, Anderson R, Nagashima Y and Narendran A. Lin28A oncogene governs stemness and metastatic potential in pediatric Neurocutaneous Melanosis - associated CNS tumors through let-7 independent mechanisms. Oncogene. Under Review ONC-2021-01913. June 2021.

Whiteside TL. Validation of plasma-derived small extracellular vesicles as cancer biomarkers. Nature Reviews Clinical Oncology. 2020;17(12):719-720. doi:10.1038/s41571-020-00433-5

Thakur S, Ruan Y, Zhang C, Lun X, Jayanthan A, Narendran A. Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells. Cancer Gene Therapy. Published online July 17, 2020:1-6. doi:10.1038/s41417-020-0199-2

Hoshino A, Kim HS, Bojmar L, et al. Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell. 2020;182(4):1044-1061.e18. doi:10.1016/j.cell.2020.07.009

Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. Lancet Oncol. 2020;21(1):134-144. doi:10.1016/S1470-2045(19)30693-X

Zhang H, Lyden D. Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. Nat Protoc. 2019;14(4):1027-1053. doi:10.1038/s41596-019-0126-x

Swift L, Zhang C, Kovalchuk O, Boklan J, Trippett T, Narendran A. Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma. Invest New Drugs. July 2019. doi:10.1007/s10637-019-00816-1

Obaid H, Kannappan S, Gupta M, et al. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors. Curr Cancer Drug Targets. November 2019. doi:10.2174/1568009619666191111153049

Jayanthan A, Hofmann B, Meier-Stephenson V, et al. Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells. J Pediatr Hematol Oncol. 2019;41(6):e359-e370. doi:10.1097/MPH.0000000000001416

Brennan L, Narendran A. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric Leukemia. Stem Cells Dev. 2019;28(19):1277-1287. doi:10.1089/scd.2019.0035

Swift L, Jayanthan A, Ruan Y, et al. Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib. Target Oncol. 2018;13(6):779-793. doi:10.1007/s11523-018-0603-0

Manley PE, Trippett T, Smith AA, et al. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatr Blood Cancer. 2018;65(9):e27217. doi:10.1002/pbc.27217

Macy ME, Kieran MW, Chi SN, et al. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study. Pediatr Blood Cancer. 2017;64(11). doi:10.1002/pbc.26621

Cooper TM, Sison EAR, Baker SD, et al. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators’ Consortium study (POE 10-03). Pediatr Blood Cancer. 2017;64(8). doi:10.1002/pbc.26414

Pearson ADJ, Federico SM, Aerts I, et al. A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. Oncotarget. 2016;7(51):84736-84747. doi:10.18632/oncotarget.12450

Singh A, Ruan Y, Tippett T, Narendran A. Targeted inhibition of MEK1 by cobimetinib leads to differentiation and apoptosis in neuroblastoma cells. J Exp Clin Cancer Res. 2015;34(1):104-104. doi:10.1186/s13046-015-0222-x

Ruan Y, Kovalchuk A, Jayanthan A, et al. Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy. Neuro Oncol. 2015;17(6):822-831. doi:10.1093/neuonc/nou310

McKenzie BA, Zemp FJ, Pisklakova A, et al. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol. 2015;17(8):1086-1094. doi:10.1093/neuonc/nou359

Hoshino A, Costa-Silva B, Shen T-L, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329-335. doi:10.1038/nature15756

Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816-826. doi:10.1038/ncb3169

Thakur BK, Zhang H, Becker A, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Research. 2014;24(6):766-769. doi:10.1038/cr.2014.44

Spence T, Perotti C, Sin-Chan P, et al. A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. Neuro Oncol. 2014;16(1):62-71. doi:10.1093/neuonc/not162

Jayanthan A, Ruan Y, Truong TH, Narendran A. Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. PLoS One. 2014;9(7):e102741-e102741. doi:10.1371/journal.pone.0102741

Triscott J, Lee C, Foster C, et al. Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. Cancer Res. 2013;73(22):6734. doi:10.1158/0008-5472.CAN-12-4331

Singh A, Lun X, Jayanthan A, et al. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol Oncol. 2013;7(3):497-512. doi:10.1016/j.molonc.2013.01.001

Macy ME, Duncan T, Whitlock J, et al. A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer. 2013;60(2):230-236. doi:10.1002/pbc.24278

Lun X, Ruan Y, Jayanthan A, et al. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. 2013;7(5):944-954. doi:10.1016/j.molonc.2013.05.004

Jayanthan A, Cooper TM, Hoeksema KA, et al. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells. Leukemia & Lymphoma. 2013;54(7):1505-1516. doi:10.3109/10428194.2012.752079

Gore L, Trippett TM, Katzenstein HM, et al. A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors. Clin Cancer Res. 2013;19(13):3649. doi:10.1158/1078-0432.CCR-12-3166

Lee C, Fotovati A, Triscott J, et al. Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice. STEM CELLS. 2012;30(6):1064-1075. doi:10.1002/stem.1081

de Oliveira JC, Brassesco MS, Scrideli CA, Tone LG, Narendran A. MicroRNA expression and activity in pediatric acute lymphoblastic leukemia (ALL). Pediatric Blood & Cancer. 2012;59(4):599-604. doi:10.1002/pbc.24167

Banderali U, Jayanthan A, Hoeksema KA, Narendran A, Giles WR. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. Journal of Neuro-Oncology. 2012;107(1):111-119. doi:10.1007/s11060-011-0735-x

Abd Elmoneim A, Gore L, Ricklis RM, et al. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatric Blood & Cancer. 2012;59(7):1252-1258. doi:10.1002/pbc.24264

Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opinion on Investigational Drugs. 2011;20(10):1455-1467. doi:10.1517/13543784.2011.613822

Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell International. 2011;11(1):44. doi:10.1186/1475-2867-11-44

Hoeksema KA, Jayanthan A, Cooper T, et al. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther. 2011;4:149-168. doi:10.2147/OTT.S21553

Farrar JE, Vlachos A, Atsidaftos E, et al. Ribosomal protein gene deletions in Diamond-Blackfan anemia. Blood. 2011;118(26):6943-6951. doi:10.1182/blood-2011-08-375170

Chaponis D, Barnes JW, Dellagatta JL, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011;104(1):179-189. doi:10.1007/s11060-010-0502-4

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. Pediatric Blood & Cancer. 2011;56(2):211-216. doi:10.1002/pbc.22723

Birks DK, Donson AM, Patel PR, et al. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol. 2011;13(12):1296-1307. doi:10.1093/neuonc/nor140

Bagatell R, Herzog CE, Trippett TM, et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011;17(3):611-619. doi:10.1158/1078-0432.CCR-10-1731

Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators’ consortium. J Clin Oncol. 2009;27(30):5102-5108. doi:10.1200/JCO.2008.20.8975

Jayanthan A, Howard SC, Trippett T, et al. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009;50(7):1174-1182. doi:10.1080/10428190902943069

Narendran A, Coppes L, Jayanthan A, et al. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J Neurooncol. 2008;90(2):171-180. doi:10.1007/s11060-008-9653-y

Jayanthan A, Fowler J, Hawkins L, et al. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. J Exp Ther Oncol. 2008;7(3):183-193. PMID: 19066127

Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res. 2007;13(6):1783-1788. doi:10.1158/1078-0432.CCR-06-1892

Reviews

Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15(2):2494-2516. doi:10.3390/ijms15022494

Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to translational advances on metastasis research. Nat Med. 2013;19(9):1104-1109. doi:10.1038/nm.3327

August KJ, Narendran A, Neville KA. Pediatric Relapsed or Refractory Leukemia: New Pharmacotherapeutic Developments and Future Directions. Drugs. 2013;73(5):439-461. doi:10.1007/s40265-013-0026-2

Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental pharmacogenomics. Pediatric Anesthesia. 2011;21(3):255-265. doi:10.1111/j.1460-9592.2011.03533.x

Gore L, Trippett TM. Emerging Non-transplant-based Strategies in Treating Pediatric Non-Hodgkin’s Lymphoma. Curr Hematol Malig Rep. 2010;5(4):177-184. doi:10.1007/s11899-010-0058-6

Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nature Reviews Cancer. 2009;9(4):285-293. doi:10.1038/nrc2621

Book chapters

Lamers F, Narendran A. Pathways of Intrinsic Apoptosis in Neuroblastoma: Targets for Therapeutics and New Drug Development | IntechOpen. In: Neuroblastoma; 2013. https://www.intechopen.com/books/neuroblastoma/pathways-of-intrinsic-apoptosis-in-neuroblastoma-targets-for-therapeutics-and-new-drug-development.

Narendran A, Leung A, Ho J. Influence and Implications of Nutrition and Metabolic Factors on the Growth and Survival of Pediatric Cancer Cells: The IGF Connection. In: Obesity and Cancer Research. Nova Science Publishers, Hauppauge NY; 2009.

Books

Lyden D, Welch DR, Psaila B. Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press; 2011. https://books.google.com/books?id=4Ds8C0yTMzoC.

Abstracts and Posters

Tran S, Thakur S, Jain M, Zhang C, Narendran A. Abstract 1121: Identification and in vivo validation of unique anti-oncogenic properties and mechanisms involving protein kinase signalling and autophagy mediated by the investigational new agent PV-10. Cancer Research. 2022;82(12_Supplement):1121. doi:10.1158/1538-7445.AM2022-1121

Sharma R, Zhang C, Maese LD, Lacayo NJ, Narendran A. Menin inhibitors as targeted therapeutics in KMT2a rearranged infant leukemia and the identification of effective treatment combinations. JCO. 2022;40(16_suppl):10024-10024. doi:10.1200/JCO.2022.40.16_suppl.10024

Sharma R, Thakur S, Jain M, Zhang C, Langevin AM, Narendran A. Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia. JCO. 2021;39(15_suppl):10033-10033. doi:10.1200/JCO.2021.39.15_suppl.10033

Satbir T, Tran S, Jain M, et al. A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children. Blood. 2020;136(Supplement 1):25-25. doi:10.1182/blood-2020-143381

Zhang C, Sharma R, Satbir T, et al. Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia. Blood. 2019;134(Supplement_1):2633-2633. doi:10.1182/blood-2019-131444

Trippett T, Berger M, Lyden D, et al. Characterization of the Genetic Landscape of Low Mutation Burden Malignancies through Multi-Parallel Genomic and Immunologic Analysis. 2018.

Trippett T, Simko S, Ye C, Caron H, Georger B. Imatrixcobi: a phase I/II, dose-escalation study of the safety, pharmacokinetics, and preliminary efficacy of cobimetinib in paediatric and young adult patients with refractory/relapsed tumor. 2016.

Kieran MW, Yao X, Macy M, et al. Final Results of a Prospective Multi-Institutional Phase II study of Everolimus (RAD001), an MTOR Inhibitor, in Pediatric Patients with Recurrent or Progressive Low-Grade Glioma. A POEITC Consortium Trial. Neuro Oncol. 2014;16(Suppl 3):iii27-iii27. doi:10.1093/neuonc/nou208.15

Trippett T, Smith A, Neville K, et al. Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors; Abstract # B81. 2013.

Pearson A, Federico S, Aerts I, et al. A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors; Abstract # 10027. 2013.

Macy M, Kieran M, Chi S, et al. A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high-grade astrocytomas; Abstract # 10030. 2013.

Hagerty M, Jayanthan A, Ruan Y, Trippett T, Narendran A. Effective targeting of PI3K/mTOR pathways with GDC-0980 in FLT-3 mutant pediatric leukemia; Abstract # C175. 2013.

Gore L, Trippett T, Katzenstein H, et al. multicenter, first-in-pediatric patients phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors; Abstract # 48828. In: ; 2010.

Bagatell R, Herzog C, Trippett T, et al. Pharmacokinetically (PK) Guided Phase 1 Trial of the IGF-1 Receptor Antagonist R1507 Administered Weekly in Children with Recurrent or Refractory Solid Tumors; Abstract# 21200. 2009.

Jayanthan A, Howard S, Trippett T, et al. Targeting the Bcl-2 family of protein in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation, and drug combination studies of the BH3 mimetic ABT-373. In: Abstract # 3626; 2008.

Trippett TM, Kuttesch J, Herzog C, et al. A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors. JCO. 2007;25(18_suppl):9547-9547. doi:10.1200/jco.2007.25.18_suppl.9547

Narendran A, Gore L, Bagatell R, et al. An Experimental Model for Target Modulation Analysis in Early Clinical Trials: Effects on Hsp90 Client Proteins in Cells of Patients Treated with 17-AAG. Vol 48.; 2007.

Gore L, Kuttesch J, Hunger SP, et al. A phase Ib study of oxaliplatin in combination with fluorouracil (5FU) and leucovorin (LV) in pediatric patients (pts) with advanced solid tumors. JCO. 2007;25(18_suppl):9548-9548. doi:10.1200/jco.2007.25.18_suppl.9548